Slide 1: C-RAD Corporate Presentation
C-RAD Corporate Presentation Tomas Blomquist, CEO┃2 September
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements regarding operational and financial performance, market conditions, and related matters. These statements reflect current expectations and are believed to be reasonable, but they are not guarantees — actual results may differ materi
Slide 3: C-RAD at a glance
C-RAD at a glance GLOBAL REVENUE H1 2026 ~20% ~50% ~30% K E Y FA C T S 2004 Uppsala ~100 Founded HQ Employees ~60 ~1,100 >2,000 Countries Customers Systems Americas EMEA APAC NASDAQ STOCKHOLM: CRAD B
Slide 4: C-RAD is part of the fight against cancer
C-RAD is part of the fight against cancer A GROWING GLOBAL CHALLENGE 2/3 20M → 28M ~50% of cancer patients new cancer cases of all cancer patients survive today; a rate per year, 2025 vs. are treated using expected to keep projected 2045 radiation therapy rising T HREE MAI N ME T HODS TO T REAT CANC
Slide 5: Strong market trends fuel oncology therapy demand
Strong market trends fuel oncology therapy demand ACC E L E RAT I N G MA R K E T D E MA N D CANCER CLINICS GLO BA L LY Rising global demand for radiotherapy Growing need for treatment efficiency and care capacity Rising demands on treatment accuracy and patient outcomes ~16,000 Proton therap
Slide 6: Advancing cancer care with Surface Guided Radiotherapy
Advancing cancer care with Surface Guided Radiotherapy A C C U R AC Y. E F F I C I E N C Y. S A F E T Y. Together with clinicians, we combine technology and care to make every patient journey safer and better. Treating a tumour demands precision: targeting cancer effectively while protecting surroun
Slide 7: End-to-end support for the radiotherapy delivery workflow
End-to-end support for the radiotherapy delivery workflow OUR PRODUCTS W E S PA N T H E RA D I O T H E RA P Y W OR K F LO W Sentinel 4DCT Simulation Plan Patient setup Treatment delivery The Starting Point Capture the patient's surface for accurate treatment setup. Catalyst⁺ HD The Eyes Sentinel 4DC
Slide 8: Trusted by leading clinics worldwide
Trusted by leading clinics worldwide E F F I CI E N T, PAT I E N T - CE N T R I C WO R K F LO W S Leading cancer treatment centres across academic, public and private healthcare rely on C-RAD to deliver them.
Slide 9: Towards a category leading open oncology workflow platform
Towards a category leading open oncology workflow platform T H R E E L AY E R S O F C - R A D ’ S E C O S Y S T E M Strengthen the core Build Evolution and refinement of C-RAD software and hardware SGRT solutions with enhanced usability and interoperability in focus Expand the value Build Partner Ne
Slide 10: Different perspectives. Shared purpose. Open interfaces.
Different perspectives. Shared purpose. Open interfaces. P A R T N E R S H I P I S N O T A T A C T I C ; I T ’ S H O W W E I N N O VA T E We bring technical expertise, our partners bring theirs. Together, we innovate at the intersection of what is technically possible and clinically valuable. Always
Slide 11: A disciplined approach to capital allocation
A disciplined approach to capital allocation D R I V I N G LON G T E R M , SUS TA I NA B LE VA LU E 1 Investment for growth Product development · Commercial, ARR and geographic expansion 2 Value through partner & buy Selective M&A · Strategic partnerships · New technologies 3 Shareholder returns Div
Slide 12: Medium-term financial goals
Medium-term financial goals Annual average organic The operating margin At least 30% of net profit growth to (EBIT margin) to be returned to exceed 10% to reach 25% shareholders
Slide 13: A focused C-RAD executive leadership team
A focused C-RAD executive leadership team Built to scale Combining industry expertise and scaling capabilities across global markets Knowledge and reach Tomas Blomquist, CEO Linda Frölén, CFO Johan Danielsson, COO Deep product knowledge, paired with commercial reach, turning what we build into what
Slide 14: Transformation program to drive growth – A new chapter for C-RAD
Transformation program to drive growth – A new chapter for C-RAD High-performance organization More efficient, more focused organization with the right skills and clear responsibilities Sales Revenue acceleration Profitability Strengthened commercial execution power with focus on selected markets an
Slide 15: Building recurring revenue on a strong growing installed base
Building recurring revenue on a strong growing installed base C-RA D ’S BUSINESS MODEL TOTAL REVENUE (M SEK) & ARR (%) Software licenses Service contracts Products 444 Services Installations Training +38% CAGR 24% Customer installed base 190 4% 76% Direct sales Distributors Partners 96% Product sale
Slide 16: Solid margins and recurring revenues underpin improved profitability
Solid margins and recurring revenues underpin improved profitability K E Y M E T R I CS, LT M Q 2 2 026 20 0% 73% 500 Products Services EBIT EBIT margin, % Revenue growth Gross margin 15 400 15% 6% EBIT FCF conversion 300 10 200 R E V E N U E S P L I T, LT M Q 2 2 0 26 5 76% 24% 100 Products Service
Slide 17: Financial highlights LTM Q2 2026
Financial highlights LTM Q2 2026 Revenue ARR Gross Margin EBIT and EBIT % 23% 24% 66 mSEK 442 2025 mSEK 45 mSEK 69% 73% 15% LTM Q2 444 10% 2026 mSEK 2025 LTM Q2 2026 2025 LTM Q2 2026 2025 LTM Q2 2026 from FY2025 from FY2025 from FY2025 from FY2025 K E Y T A K E AW A Y S • Restructuring largely compl
Slide 18: Executive summary
Executive summary A global leader in Surface Guided Radiation Therapy and #1 in proton therapy Leading global SGRT player • Works with any RT treatment system • Trusted by top cancer clinics globally Large underpenetrated growing market with long revenue runway Rising cancer incidence • Growing need
Slide 19: Q&A
Q&A